<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02042196</url>
  </required_header>
  <id_info>
    <org_study_id>06-0537 SHAPE2</org_study_id>
    <secondary_id>R56HL114073-06A1</secondary_id>
    <nct_id>NCT02042196</nct_id>
  </id_info>
  <brief_title>Sex Hormones and Atherosclerosis Prevention in Perimenopausal Women</brief_title>
  <acronym>SHAPE2</acronym>
  <official_title>Biological Mechanisms of Vascular Dysfunction With Age and Estrogen Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      As women get older and go through menopause, levels of the female reproductive hormone&#xD;
      estradiol decrease to low levels. Also with aging, the functioning of the arteries declines.&#xD;
      Over time this vascular dysfunction can lead to health problems such as high blood pressure&#xD;
      and heart disease. This study is being done to help determine what causes arteries to become&#xD;
      unhealthy in postmenopausal women, who have low levels of the female reproductive hormone&#xD;
      estradiol. In this study we will test whether low levels of tetrahydrobiopterin (BH4), a&#xD;
      natural substance in the body that can cause the arteries to expand, explains why arteries&#xD;
      become unhealthy in women with low levels of estradiol. To answer this question, we will&#xD;
      study how vascular function changes with a medication that causes a short-term increase in&#xD;
      BH4 levels when estradiol is lowered with a medication, compared to when estradiol is normal.&#xD;
      We will also determine whether the administration of the antioxidant vitamin C, along with&#xD;
      the medication to increase BH4 levels, will normalize vascular health in perimenopausal and&#xD;
      postmenopausal women, and in women who have their estradiol levels lowered.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Endothelial dysfunction, featuring reduced vascular endothelial-dependent dilation (EDD), is&#xD;
      a significant predictor of cardiovascular (CV) events. Reduced EDD is characterized by the&#xD;
      loss of nitric oxide (NO) production. EDD declines with aging in women at a slower rate&#xD;
      compared to men but rapidly declines after menopause and quickly catches up to men,&#xD;
      suggesting a beneficial effect of estrogen (E2). Our research has investigated the mechanisms&#xD;
      underlying endothelial protection of E2 including how hormonal fluctuations during the&#xD;
      peri-to early postmenopausal years contribute to endothelial dysfunction, and how these&#xD;
      hormonal changes might interact with aging. Using a well described experimental model&#xD;
      (systemic infusion of ascorbic acid; AA) to acutely reduce reactive oxygen species (ROS), our&#xD;
      preliminary findings implicate oxidative stress as an underlying mechanism explaining the&#xD;
      impaired EDD during the menopausal transition. Specifically we found improved EDD in response&#xD;
      to AA in late peri- and postmenopausal women but not in pre- or early perimenopausal women.&#xD;
      These data indicate that E2 may protect the vasculature from free radical injury during pre-&#xD;
      and early perimenopausal years. In support of this concept, we demonstrated that AA can&#xD;
      reverse the decrease in EDD that occurs in the setting of short-term E2 deficiency (3-days of&#xD;
      gonadotropin releasing hormone antagonist; GnRHant) in pre-and early perimenopausal women.&#xD;
&#xD;
      Tetrahydrobiopterin (BH4) is a critical co-factor in the production of NO by endothelial&#xD;
      nitric oxide synthase (eNOS), and in the face of deficient levels, uncoupling of eNOS results&#xD;
      in the production of ROS instead of NO. Whether the increased ROS and impaired EDD that&#xD;
      occurs during the peri- and early postmenopausal periods is associated with reduced vascular&#xD;
      BH4 is at present unknown. However, our finding that AA could not improve the reduced EDD&#xD;
      found in early perimenopausal women or restore EDD in peri-and postmenopausal women to&#xD;
      premenopausal levels, indicates that other sources of ROS or causes of low NO are involved in&#xD;
      the impaired EDD across the stages of the menopause transition and aging in women. In vitro&#xD;
      studies demonstrate that the co-administration of BH4 and AA completely prevents the eNOS&#xD;
      uncoupling and decreased NO production in endothelial cells treated with a peroxynitrite&#xD;
      (ONOO-) donor, compared to administering either one alone. The global aim of this renewal is&#xD;
      to follow-up on our previous findings and to determine the role of BH4 as a mediator of&#xD;
      endothelial dysfunction [across the stages of the menopausal transition and aging in women.&#xD;
      This global aim will be addressed by 3 specific aims (SA). Using a cross-sectional design,&#xD;
      SA1 will measure EDD in healthy pre-, peri- and postmenopausal women: 1) under basal&#xD;
      conditions; and 2) following an acute increase in BH4. SA2 will expand on the cross-sectional&#xD;
      comparisons via short-term (10 days) ovarian suppression (GnRhant) in pre-and early&#xD;
      perimenopausal women to isolate the age-independent effects of E2. SA3 will examine whether&#xD;
      co-administration of BH4 and AA fully restore youthful EDD in peri-and postmenopausal women.&#xD;
&#xD;
      SA1: To determine the possible mechanistic involvement of BH4 deficiency in the decline in&#xD;
      endothelial function during the peri-and early postmenopausal period and its potential&#xD;
      relation to oxidative stress. This will be assessed by comparing brachial artery EDD and&#xD;
      plasma and endothelial cell markers of oxidative stress and NO (see methods for details) in&#xD;
      healthy pre-, peri-and postmenopausal women: 1) under basal conditions; and 2) in response to&#xD;
      acute oral BH4 (vs PL) supplementation.&#xD;
&#xD;
      Hypothesis1 (H1): a) EDD will increase in response to BH4 in early peri, late peri and&#xD;
      postmenopausal women but not premenopausal women. b) The increase in EDD in response to BH4&#xD;
      will be associated with a decrease in plasma markers of oxidative stress. c) The reduced EDD&#xD;
      in peri- and postmenopausal women will be associated with lower endothelial cell markers of&#xD;
      NO and higher oxidative Stress.&#xD;
&#xD;
      SA2: To determine whether the decrease in EDD in response to acute ovarian suppression in&#xD;
      pre- and early perimenopausal women is related to reduced BH4 bioavailability and elevated&#xD;
      markers of oxidative stress. This will be assessed by comparing EDD and plasma markers of&#xD;
      oxidative stress after acute oral supplementation of BH4 (or PL) following either acute&#xD;
      ovarian suppression with (GnRHant+E2) or without (GnRHant+PL) E2 add-back. Additionally,&#xD;
      endothelial cell protein expression of markers of BH4 biosynthesis and oxidative stress will&#xD;
      be measured before and after the suppression/add-back paradigm.&#xD;
&#xD;
      H2: a) The expected decrease in EDD and increase in plasma oxidative stress markers following&#xD;
      acute ovarian suppression will be mitigated in the groups treated with oral BH4&#xD;
      (GnRHant+PL+BH4); there will be little or no effect of the addition of BH4 to the E2 add-back&#xD;
      group. b) Ovarian suppression alone will reduce endothelial protein markers of BH4&#xD;
      biosynthesis and will increase markers of oxidative stress. These changes will not be&#xD;
      observed following ovarian suppression with E2 add-back and oral BH4. These sets of&#xD;
      experiments will provide evidence that the oxidative stress-related decrease in EDD in&#xD;
      response to E2 suppression is in part, related to decreased BH4 bioavailability.&#xD;
&#xD;
      SA3: To determine whether the co-administration of BH4 with AA will completely restore EDD in&#xD;
      peri-and postmenopausal women, and in early perimenopausal women following ovarian&#xD;
      suppression.&#xD;
&#xD;
      H3: The co-administration of BH4 with AA will restore EDD to premenopausal levels a) in&#xD;
      peri-and postmenopausal women, and b) in early perimenopausal following acute ovarian&#xD;
      suppression.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">May 2, 2016</completion_date>
  <primary_completion_date type="Actual">May 2, 2016</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in brachial artery flow-mediated dilation</measure>
    <time_frame>4-5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in carotid artery compliance and endothelial cell protein expression</measure>
    <time_frame>4-5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Menopause</condition>
  <condition>Aging</condition>
  <arm_group>
    <arm_group_label>Pre or Early perimenopausal 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Baseline experiment: Subjects randomized to either 1) KUVAN (10mg/kg body weight) crossover to placebo OR 2) placebo crossover to KUVAN&#xD;
Hormone modification: GnRH antagonist with Cetrotide (0.25mg/d) + placebo transdermal patch, then subjects randomized again to either 1) KUVAN crossover to placebo OR 2) placebo crossover to KUVAN</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pre or Early Perimenopausal 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Baseline experiment: Subjects randomized to either 1) KUVAN crossover to placebo OR 2) placebo crossover to KUVAN&#xD;
Hormone modification: Estrogen add-back with Cetrotide + Climara (0.075mg/d), then subjects randomized again to either 1) KUVAN crossover to placebo OR 2) placebo crossover to KUVAN</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Late Perimenopausal and Postmenopausal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects randomized to either 1) KUVAN crossover to placebo OR 2) placebo crossover to KUVAN&#xD;
No hormone modification.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KUVAN</intervention_name>
    <description>KUVAN will be given orally at 10mg/kg dose per body weight. KUVAN will be dissolved in 4-8oz water and consumed within 15 minutes.</description>
    <arm_group_label>Late Perimenopausal and Postmenopausal</arm_group_label>
    <arm_group_label>Pre or Early Perimenopausal 2</arm_group_label>
    <arm_group_label>Pre or Early perimenopausal 1</arm_group_label>
    <other_name>Tetrahydrobiopterin or BH4</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo pills designed to match the dissolvable KUVAN pills</description>
    <arm_group_label>Late Perimenopausal and Postmenopausal</arm_group_label>
    <arm_group_label>Pre or Early Perimenopausal 2</arm_group_label>
    <arm_group_label>Pre or Early perimenopausal 1</arm_group_label>
    <other_name>Control</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetrotide</intervention_name>
    <description>Cetrotide (0.25mg/d) will be taken daily for 10 days via abdominal subcutaneous injection.</description>
    <arm_group_label>Pre or Early Perimenopausal 2</arm_group_label>
    <arm_group_label>Pre or Early perimenopausal 1</arm_group_label>
    <other_name>Cetrorelix acetate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Climara</intervention_name>
    <description>0.075mg/d transdermal patch will be placed on skin.</description>
    <arm_group_label>Pre or Early Perimenopausal 2</arm_group_label>
    <other_name>Estradiol transdermal patch</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo transdermal patch</intervention_name>
    <description>Inactive transdermal patch</description>
    <arm_group_label>Pre or Early perimenopausal 1</arm_group_label>
    <other_name>Control</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age criteria established for pre-, peri- and postmenopausal women, and if&#xD;
             postmenopausal at least 1 year beyond menopause&#xD;
&#xD;
          -  resting blood pressure &lt;140/90 mmHg 81; 2) plasma glucose concentrations &lt;110 mg/dl&#xD;
             under fasting conditions&#xD;
&#xD;
          -  sedentary or recreationally active (&lt;3 days of vigorous aerobic exercise)&#xD;
&#xD;
          -  no use of OCs, HT, or other medications that might influence cardiovascular function&#xD;
&#xD;
          -  nonsmokers&#xD;
&#xD;
          -  no use of vitamin supplements, NSAIDS or willing to stop use for duration of the study&#xD;
&#xD;
          -  not taking any other medications that would interact with cetrotide, E2 patch, or&#xD;
             KuvanÂ® to confound interpretation of results&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  history of or active estrogen-dependent neoplasms, acute liver or gallbladder disease,&#xD;
             vaginal bleeding, venous thromboembolism, hypertriglyceridemia, and CVD&#xD;
&#xD;
          -  known allergy to transdermal patch, GnRHant (i.e., hypersensitivity to cetrorelix,&#xD;
             extrinsic peptide hormones, mannitol, GnRH, benzyl alcohol - the vehicle for injection&#xD;
             of cetrorelix), or KUVAN&#xD;
&#xD;
          -  history of stomach ulcer or bleeding&#xD;
&#xD;
          -  other contraindications to HRT, GnRHant, and KUVAN (i.e., taking Levodopa, medications&#xD;
             that can inhibit folate metabolism including methotrexate)&#xD;
&#xD;
          -  pregnant or currently breastfeeding&#xD;
&#xD;
          -  Other conditions for which individuals will be excluded from the study include:&#xD;
             diabetes, active infection, history of seizures or disease that affects the nervous&#xD;
             system, sepsis or an abnormal resting ECG&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kerrie Moreau, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>January 17, 2014</study_first_submitted>
  <study_first_submitted_qc>January 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2014</study_first_posted>
  <last_update_submitted>July 9, 2019</last_update_submitted>
  <last_update_submitted_qc>July 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>endothelial function</keyword>
  <keyword>women</keyword>
  <keyword>estrogen deficiency</keyword>
  <keyword>sex hormones</keyword>
  <keyword>adiposity</keyword>
  <keyword>oxidative stress</keyword>
  <keyword>antioxidants</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetrorelix</mesh_term>
    <mesh_term>Estradiol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

